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The 20th century has seen an explosion in medical knowl- 
edge, spurred by advances in science and new technology, 
resulting in better diagnostic methods and treatment ad- 
v,mces. The outcome has been to extend life and improve 
qu~ty of life for people, particularly those with heart 
dtsease. Life expectancy at birth is now approaching 77 
)cars, from less than 70 years of age in 1960, and less than 
50 years in 1900 (1). The value of advances in medicine is 
uvidenced by the growth in medical care services from less 
than 6% of the U.S. economy in 1960 to 14% of the gross 
d,mestic product (GDP), now exceeding $1 trillion a year 
it). 
The success of advances in the diagnosis and treatment of
heart and vascular disease is reflected in part by declining 
,~verall mortality for acute myocardial infarction and other 
diqeases of the heart. Even so, heart disease remains the 
leading cause of death for Americans and other people 
,m~und the world (1). However, because of demographic 
changes and the ability to treat previously fatal conditions, 
absolute numbers of people living with cardiovascular dis- 
u.,tse will increase in the near future (2). The cost-related 
m~pact of these changes is examined in this report. 
Expected advances in prevention and treatment technol- 
t~gies are exciting and promise to further reduce heart 
disease-related mortality and morbidity. In this report, we 
c\amine the cost impact of possible future scenarios. En- 
thusiasm must be tempered, however, by the knowledge 
that life is limited and there will be competing causes of 
death, including cancers, Alzheimer's disease, and other 
&seases. Our examination of the current and future cost of 
heart disease is limited to direct medical care cost, including 
the cost of services related to prevention, diagnosis, treat- 
ment, and rehabilitation of people with heart disease. No 
c~timates will be made regarding the substantial indirect 
cost of heart disease to society, including the cost of lost 
opportunities related to disability and premature death from 
heart disease. 
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Using three scenarios of the future, we examine potential 
cost implications of some future advances in cardiac sciences 
in 2010 and 2025. We have chosen to estimate future cost 
using three different scenarios to simplify assumptions and 
decrease confounding information. We recognize that these 
models are based on assumptions and that the most likely 
future reality will include some aspects of all the scenarios. 
Scenario 1 describes the demographic changes facing the 
U.S. The average age of the U.S. population is increasing, 
and the percentage ofthe population over age 65 is growing 
rapidly. Because the prevalence of heart disease increases 
with age, as do health care utilization and cost, aging alone 
will contribute to a substantial increase in cost. The impact 
of demographic and other factors is calculated using 1999 
data. 
Scenario 2 examines the potential impact of advances in 
prevention that might lead to new drugs or gene therapies 
for preventing atherosclerosis and coronary artery disease 
(CAD). These would complement or replace current med- 
ications used to control diabetes, obesity, high blood pres- 
sure, and high cholesterol, thereby preventing heart attacks, 
strokes, and renal failure. These projections also are based 
on 1999 data. 
Scenario 3 examines the potential impact of improve- 
ments in treatment, including new drugs to treat heart 
failure and widely available heart transplantation, which 
would rely more heavily on swine hearts. 
The three scenarios then are combined to provide an 
estimate of the combined effects of demographic changes 
and improvements in prevention and treatment in 2010 and 
2025. 
METHODOLOGY 
Our methods for projecting the future cost of heart disease 
are based on the most recently available cost data, projecting 
costs to 1999 so that it can be used as the base year. Future 
cost increases or decreases in 2010 and 2025 are projected, 
using 1999 dollars and ignoring the effects of future infla- 
tion in prices. 
We have chosen to model future costs of heart diseases, 
including CAD, congestive heart failure, and part of hyper- 
tensive disease, as well as other "heart" diseases. Using the 
ICD-9 CM disease classification, our analysis included 
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codes from 391-398, 402, 404, 410-416, and 420-429. 
Excluded are congenital nomalies of the heart, symptoms 
that might involve the cardiovascular system, and renal and 
pulmonary sequelae. 
In some cases, it is not possible to obtain information on 
utilization and cost of heart disease alone, but information is
available on all cardiovascular diseases, including heart 
disease, hypertensive disease, and cerebrovascular disease. 
When possible, cost information is provided on all cardio- 
vascular diseases as well as heart disease alone; heart disease 
accounts for 60% of the cost of all cardiovascular disease 
(3,4). 
Our work builds directly on the work of Hodgson and 
Cohen (3), who took the total health care cost in 1995 and 
identified the proportion represented by all cardiovascular 
diseases (16.9%) and by heart disease alone (10%). The 
projections made by the American Heart Association for 
1999 (4) use the work of Hodgson and Cohen to predict 
1999 cost for heart disease and for all cardiovascular 
diseases. 
To simplify the comparison of costs over time, all future 
costs are stated in terms of 1999 dollars. This simplification 
holds the value of the dollar constant, ignoring any future 
effects of inflation on the value of a dollar and on total 
health care cost. In the calculation of the cost-effectiveness 
of prevention (scenario 2), future cost is discounted at the 
rate of 3% per year to estimate present value. 
A generally accepted measure of effectiveness or benefits 
from a life-saving medical intervention is the number of 
quality-adjusted life years (Q_ALYs) added to the patient's 
life. The Q ALY is the number of years added to life, 
including an adjustment to take into account he extent of 
disability, pain, or other limitations. This adjustment can be 
made using patient utilities for different health states; for 
example, one year of additional life with angina (without 
congestive heart failure) is equivalent to 0.84 Q_ALYs (5). 
Our scenarios wiU use Q_ALYs to calculate the cost of 
preventive interventions per Q_ALY. 
Various costs of care are estimated for major categories of 
service, including hospital (inpatient and outpatient), phy- 
sician, nursing home, drugs, home health, and other health 
care costs using national data sources (6). Costs include all 
services paid for by Medicare, Medicaid, and private insur- 
ance, as well as out-of-pocket xpenditures paid by patients. 
The overall contribution of circulatory system disease to 
total U.S. health care expenditures is discussed. 
RESULTS 
Total U.S. Health Care Expenditures 
The U.S. health care system is the most expensive in the 
world. The U.S. spent over 14% of its GDP, or one in every 
seven dollars, on health care in 1998. Total health care 
expenditures are approximately $1 trillion, divided among 
the following: hospital care, 38%; physician services, 22%; 
other professional and dental services, 12%; drugs, 11%; 
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Figure 1. Distribution of total U.S. health care expenditures by
type of service (HCFA 1999). 
nursing home and home health care, 12%; and other costs, 
5% (Fig. 1). The fastest growing category is drugs, whereas 
the growth in home health care has slowed, and expendi- 
tures for hospital and physician services now account for a 
smaller proportion of total costs than they did in 1990 (6). 
Hospital expenditures declined from 42% of total health 
care expenditures in 1990 to 38% by 1997, and physician 
expenditures declined from 24% in 1990 to 22% by 1997. 
Expenditures for Heart Disease 
Extrapolating forward to 1999, total U.S. health care 
expenditures are expected to be $1,059 billion, of which 
$178 billion (16.8%) will be for all cardiovascular diseases 
and $102 billion (9.6%) will be for heart disease alone (4). 
Hospital care, including inpatient medications, is expected 
to account for 60% of the cost of heart disease, and the 
remaining 40% breaks down as follows: 13% for physician 
services, 7% for outpatient drugs, 4% for home health care, 
and 16% for nursing home care (Fig. 2). 
Hospital Sewices 
Inpatient services. The most recent hospitalization data 
show that there were 6.1 million discharges for all cardio- 
vascular diseases, representing 19.7% of the 30.9 million 
60% 
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Figure 2. Distribution of U.S. health care expenditures forheart 
diseases by type of service, 1999 estimates (AHA 1998). 
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hospital discharges in 1997. Heart disease accounted for 4.2 
million discharges, or 13.6% of all hospital discharges, 
occurring at the rate of 1,550 discharges per 100,000 
population (7). Americans received 5.4 million inpatient 
cardiovascular p ocedures, with some of the frequent cardiac 
procedures being coronary artery bypass graft (CABG) 
surgeries on 366,000 patients, 1.1 million cardiac atheter- 
~zations, and 317,000 pacemaker insertions or replacements. 
As would be expected, cardiovascular p ocedure rates were 
h,ghest among patients age 65 and older (8,608 per 
100,000), and the number of procedures declines with 
.wronger age (3,297 for ages 45-64, and less than 50 per 
100,000 for patients under 45 years). 
Ambulatory surgery. Operative and diagnostic procedures 
.~re being done more frequently on an outpatient basis and 
no longer equire hospitalization, even though most ambu- 
latory surgery is done in a hospital facility. In 1996, 898,000 
(2.9%) of the 31.5 million procedures done in ambulatory 
.,cttings, or 340 per 100,000 persons, were operations on the 
cardiovascular system (8). The most frequently performed 
cardiac procedure was catheterization, which accounted for 
472,000 (52.6%) of these procedures. Adding together 
inpatient and ambulatory catheterization procedures, the 
total was 1.57 million in 1997, or an overall rate of 600 per 
100,000. 
Emergency and outpatient department services. In 1997, 
4.5 million patient visits (4.7% of all visits) to hospital 
emergency departments were diagnosed as cardiovascular 
disease (9). This figure represents 1,700 visits per 100,000 
people per year. In addition, there were 77 million visits to 
hospital outpatient departments in 1997. Cardiovascular 
disease accounted for 4.8 million of the 77 million visits 
(~.6%), or 1,800 visits per 100,000 people per year. One of 
tile most commonly occurring diagnoses was essential hy- 
pertension (3.1 million visits), which accounted for a ma- 
j,~rity of all cardiovascular disease visits (10). 
Projected 1999 expenditures for hospital services. Pro- 
jccting expenditures from 1997 to 1999, hospital costs are 
expected to be $60.3 billion for heart disease and $89.2 
billion for all cardiovascular disease. Total U.S. hospital 
costs in 1999 are expected to be $395 billion, of which 
cardiovascular disease will comprise 22.6%, including 15.3% 
fi~r heart disease. 
Physician Services 
Statistics are available for physician office-based services; no 
comparable data are available for inpatient physician services 
in the U.S. In 1997, there were 787 million office visits to 
physicians (11). Including aU physician specialties, the 
primary diagnosis for 80.2 million physician visits was 
cardiovascular disease, representing 10.2% of all physician 
office visits, or 30,000 per 100,000 people. These diagnoses 
included 29.7 million visits (3.5%) for hypertension; 10.7 
million (1.4%) for ischemic heart disease; and 9.2 million 
(1.2%) for other heart diseases, excluding ischemia. Physi- 
cians identifying themselves as cardiovascular specialists 
reported 17.3 million visits, or 2.2% of the 787 million 
physician visits, representing 6,500 visits per 100,000 peo- 
ple. Drugs were prescribed uring 83% of these visits, with 
an average of 4.6 drugs prescribed per visit. 
Projected 1999 physician expenditures for all cardiovas- 
cular disease are $26.8 billion; for heart disease alone, 
expenditures total $13.8 billion (4). Total physician expen- 
ditures are expected to be $233 billion in 1999, with 11.5% 
for all cardiovascular disease and 5.9% for heart disease. 
Prescription Drugs 
Prescription drug cost is rising more rapidly than other 
health expenditure. In 1999, outpatient prescription cost 
was expected to be $6.6 billion for heart disease (6.5% of 
total heart disease cost) and $16 billion for all cardiovascular 
disease, accounting for 9% of all cardiovascular disease costs 
(4). As a percentage of total 1999 U.S. health care expen- 
ditures, outpatient heart disease drugs represent 0.6%, and 
all cardiovascular disease drugs account for 1.6%. 
Nursing Homes and Home Health 
In 1995, 1.39 million Americans were nursing home resi- 
dents (7). A primary diagnosis of cardiovascular disease was 
given to 27.1% of these individuals, including 10.9% with 
heart disease, 2.4% with cerebrovascular disease, and 3.6% 
with essential hypertension. Projecting to 1999, nursing 
home cost for heart disease is expected to be $16.1 billion, 
and nursing home cost for all cardiovascular disease will 
likely be $35.1 billion. Total nursing home cost is expected 
to be $90.1 billion in 1999, with 39% being spent on all 
cardiovascular disease and 17.9% on heart disease. 
In 1996, 2.5 million patients were using home health or 
hospice services, with a total of 8.2 million discharges from 
care occurring during the year (12). Classifying the 2.5 
million patients by primary diagnosis reveals that 623,000 
(25%) had cardiovascular disease, with 268,000 (10.8%) 
having heart disease and 108,000 (4.3%) having essential 
hypertension. Projected 1999 home health expenditures for 
heart disease are $4.0 billion, and $8.9 billion for all 
circulatory diseases. 
Trends in Utilization 
The growth in cardiovascular p ocedure volumes has been 
substantial over the past two decades. While volume for 
many procedures has doubled or tripled during this time 
period, hospitalization for cardiovascular disease has grown 
modestly. In 1979, there were approximately five million 
discharges with a principal diagnosis (first listed) of cardio- 
vascular disease; by 1997, this number had increased only 
20% to 6.1 million. The same trends occurred for CAD 
discharges and stroke. By contrast, discharges for congestive 
heart failure have approximately doubled from 1979 to 
1997, totaling more than 900,000 in 1997 (4). 
Hospitalizations have not increased as much as proce- 
dural volumes, partially because of the movement of proce- 
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Table 1. Estimated U.S. Population Age Distribution and Prevalence ofHeart Disease: 1990- 
2025 (2) 
Prevalence Percent Males 
Percent of U.S. of Heart Heart Disease With Heart 
Population Age 65+ Disease Prevalence (millions) Disease 
2000 12.6% 16.4% 23.4 49.9% 
2010 132.% 15.6°/6 27.1 51.1% 
2025 18.3% 16.8% 34.3 52.2% 
dures to ambulatory care settings. In 1996, 898,000 ambu- 
latory procedures were performed on the cardiovascular 
system, and there were more than five million inpatient 
procedures. One of the high-volume procedures i cardiac 
catheterization, with 1.1 million inpatient procedures done 
in 1997. The most recent data available (1996) indicate that 
an additional 472,000 procedures were done in ambulatory 
surgery settings for a total number of catheterizations at 
more than 1.5 million procedures. This estimate represents 
an overall growth in cardiac atheterization procedures since 
1979 of greater than 315% (4). In 1997, 366,000 patients 
underwent CABG surgery, representing anincrease of more 
than 228% since 1979. Similar trends were noted for heart 
transplantation. I  1997, 2,290 heart transplants were per- 
formed in the 275 U.S. transplant centers, compared with 
57 in 1980. The numbers of transplants performed continue 
to fall far short of the estimated requirement of 40,000 
among those age 65 and younger (12,4). Growth in proce- 
dure rates is expected to continue to grow faster than 
hospital discharges in the near future. 
1999 Heart Disease Costs: Summary and Limitations 
Resources pent on services to prevent, diagnose, treat, or 
rehabilitate individuals with heart disease were expected to 
be $102 billion in 1999, accounting for approximately 10% 
of total U.S. health care expenditures. The majority were for 
hospital care (60%), followed by nursing home (16%) and 
physician services (13%), as shown in Figure 2. Cardiovas- 
cular procedures are being done more often in ambulatory 
surgery settings, most of which are hospital based. Other 
factors contributing to changes in the diagnostic mix of 
heart-disease patients admitted to hospitals include mortal- 
ity trends. In particular, as the mortality rate for acute 
myocardial infarction has declined in recent years, there has 
been a growth in admissions for congestive heart failure. As 
a result there is greater demand for heart transplants, 
currently the most costly heart disease intervention. The 
high cost is not primarily from the complexity of the 
procedure or physician charges but instead is from drug 
costs and long hospital stays. 
Our estimates of the future cost of heart disease were 
based on the 1999 cost of heart disease. The national 
averages used mask substantial variability in practice by 
geographic region. Several factors contribute to these vari- 
ations, including eographic differences in the availability of 
services, differences in ability to pay and insurance coverage, 
and differences in physician practice patterns (13-15). One 
concern is that not all needs for cardiovascular care are 
currently being met. To the extent hat the current health 
care system is failing to meet needs, our estimates of future 
use and cost of heart disease care will be understated. 
Scenario 1: Impact of Population Changes 
Scenario. The growth and aging of the U.S. population is
expected to contribute to increased cost for the care of heart 
disease. In Table 1, Foot (2) estimates that the prevalence of
heart disease (16.4% of the U.S. population in 2000) will 
change relatively tittle in 10 years (15.6%) and in 25 years 
(16.8%). However, because of a growing population, the 
number of people with heart disease is expected to increase 
from 23.4 million in 2000 to 27.1 million in 2010 and 34.2 
million in 2025. 
Assumptions and calculations. The estimated cost of 
heart disease in 1999 is $101.8 billion, including hospital, 
physician, drug, nursing home, and other health care costs. 
This cost equals approximately $4,350 per person with heart 
disease. Projecting the per-person cost to 2010 and 2025 
results in total costs of $118 billion and $149 billion, 
respectively. These projections assume the same rates of 
diagnosis and treatment, and use of the same technologies a
today. This calculation provides an estimate of the cost 
impact of demographic hanges alorie, including some 
increase in overall longevity, but no heart disease-specific 
changes in mortality. 
Impact on costs. Demographic changes will lead to a 15% 
increase in expenditures for heart disease treatment by 2010 
and a 46% increase by 2025, as measured in 1999 dollars. 
Scenario 2: Impact of Improvements 
in Prevention of Cardiovascular Disease 
Scenario. Let us assume that there are new "magic-bullet" 
drugs or nutriceuticals available by 2010 that can be taken by 
those with risk factors to prevent atherosclerosis and CAD. 
The drug cost is high, estimated to be $250 per month or 
approximately $8 per day in 1999 dollars. Future savings 
would be expected to occur because of the reduction in acute 
myocardial infarction and invasive treatments for CAD. By 
2010, there would be little impact, but by 2025 the 
prevalence of CAD will have declined by 25%. Prevention 
of CAD is expected to add an average of two Q_ALYs for 
people without CAD. 
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Assumptions and calculations. Currently 50% of people 
with heart disease have atherosclerotic disease. We assume 
rlae preventive drug or drugs will be taken by 50% of those 
who would be expected to benefit, and about 25% of 
ischemic disease and its costs will be prevented by 2025. 
Coronary artery disease (ICD-9: 410-414) affects ap- 
proximately half of those with heart disease and accounts for 
51% of the total heart disease cost, estimated to be $51.9 
billion in 1999 and $75.8 billion in 2025 if no preventive 
drugs are available. The potential is to save at least a quarter 
of this amount, or $19 billion, in 2025 with prevention. 
Among patients with CAD (estimated to be 17.2 million 
people or 8.4% of the population), we assume that half (8.6 
million or 4.2% of the population) will take the drug 
rcg~arly, and for one quarter (4.3 million or 2.1%) the 
d~sease will be prevented and cost of treatment saved. The 
c,~st of the drug or drugs for 8.6 million people would be 
$25.8 billion annually. Other costs would include periodic 
physician visits, which many of these individuals would 
already have. Before 2025, we assume, drug costs would be 
u~curred for 15 years before any substantial savings would be 
a~hieved through prevention of subsequent CAD. 
Cost impact. In 2010, an additional $25.8 billion a year 
wlU be spent for the preventive drug or drugs, adding 22% 
t,, heart-disease expenditures that year. No savings are 
~pected before 2025, when CAD expenditures would be 
reduced by $19 billion because of prevention, but the 
c~mtinuing medication cost of $25.8 billion annually results 
i~ a net increase in cost of $6.8 billion in 2025. This figure 
r~'presents anoverall increase in 2025 heart-disease cost of 
_q"/0. If the cost of drugs is 50% lower than projected ($4 a 
day or $125 a month), there will be a net savings in 2025 of 
S().1 billion or 4% of 2025 projected heart disease cost. 
However, if the cost of drugs is 50% higher, then overall 
~, ~st would increase $19.7 billion, adding 13% to 2025 costs. 
Cost-effectiveness. The preventive drug is assumed to be 
taken starting in 2010 for 15 years before the expected onset 
,ff CAD and for the next 10 years of life, adding two good 
years of life for 25% of the people who would have 
&'veloped CAD. Future cost would be discounted at the 
rate of 3% per year. 
The cost per Q_ALY from prevention would be $41,000. 
lftbe cost of drugs is 50% lower ($4 a day), then the cost per 
O~ALY would decrease to $14,500, whereas a 50% increase 
in the cost of drugs ($12 a day) would increase the cost per 
Q ALY to $68,000. 
Scenario 3: Imt~act of 
Improvements in Treatment Technologies 
Scenario 3A. Suppose medications that reverse heart fail- 
ure become available by 2010, and by 2025 these drugs have 
reduced hospitalizations for congestive heart failure. As- 
suming that the cost of medication is $250 a month or 
approximately $8 a day in 1999 dollars and there is 50% 
compliance, the potential savings could be 40% of conges- 
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tire heart failure hospital cost. Physician charges and other 
costs would be expected to remain about he same. 
Assumptions and calculations. I f  no changes in treatment 
occur by 2025, hospital costs for congestive heart failure are 
expected to be 11.3% of the total heart disease cost of $149 
billion. Taking 40% of the $16.8 billion congestive heart 
failure hospital cost provides an estimate of $6.7 billion in 
potential savings. To estimate the cost of the new drug, 
assume that approximately 20% of people with heart disease 
who have congestive heart failure, or 6.8 million people, 
would be treated in 2025. Assuming 50% compliance with 
the fitll prescription, the drug cost would be $10.2 billion in 
2025. 
Cost impact. In 2025, treatment of congestive heart failure 
will increase costs by $3.5 billion, adding 2% to the total 
projected heart disease cost. If the cost of drugs is 50% lower 
($4 a day), then there will be a net savings of $1.6 billion; a 
50% increase in the cost of drugs ($12 a day) would lead to 
an overall increase of $8.6 billion in the cost of heart disease. 
Scenario 3B. Assume that by 2010, swine heart ransplan- 
tation has become common at roughly half the cost of a 
human transplant and that by 2025, the use of organs from 
swine has surged from a few thousand in 2010 to approxi- 
mately 58,000 transplants a year, meeting the full demand. 
Assumptions and calculations. Assume transplant costs 
average $150,000 per transplant, plus $10,000 per year for 
ongoing medical management. This estimate is somewhat 
more than half of the 1996 costs reported: $253,000 in the 
first year, with annual follow-up costs of $21,200 per year 
(12). In 1996, it was estimated that 40,000 people, or about 
1,700 per 100,000 people with heart disease, needed re- 
placement hearts each year, but only 5% of those needing a
transplant received one. By 2025, it is assumed that all 
patients who need a transplant will have one, which will 
represent about 58,000 transplants a year at that time. 
Assuming that people live an average of 10 years with a 
transplanted heart, there will be approximately 522,000 who 
will need ongoing medical management. The estimated 
annual costs for transplantation will be $8.7 billion in 1999 
dollars, and the annual medical management cost will be 
$5.2 billion, totaling $13.9 billion. Assume that this aggres- 
sive heart transplant program reduces the total cost of 
treating congestive heart failure by 50%. Congestive heart 
failure represents 18.7% of all heart disease costs, projected 
to total $149 billion in 2025. The savings would be 9.35% 
of the $149 billion ofaU heart disease costs, or $13.9 billion 
in 2025. 
Cost impact. In 2025, the cost of heart transplants will 
equal the cost savings expected to be achieved by an 
expected 50% reduction in total expenditures for congestive 
heart failure. I f  reductions in congestive heart failure expen- 
ditures were to be greater than 50%, then there would be a 
net savings; less than 50% reductions would increase costs 
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over savings. However, if the cost of heart ransplants does 
not decline by 50%, as predicted, then the additional cost 
would be $14.5 billion at current value (1999 dollars), 
adding 9.7% to total heart disease costs in 2025. 
Combined Scenarios for Demographic 
Changes, Prevention, and Treatment 
Scenario. The future is likely to represent the combined 
effects of demographic changes (Scenario 1), possible ad- 
vances in the prevention of atherosderosis and CAD (Sce- 
nario 2), and possible advances in the treatment of heart 
failure and heart transplantation (Scenario 3). 
Assumptions and calculations. Assuming that a 25% re- 
duction in CAD is achieved by 2025 (Scenario 2), for 
purposes of cost calculations we assume that this reduction 
will lead to a 50% reduction in congestive heart failure and 
a 50% reduction in the need for heart transplants. 
In 2010, demographic changes will have increased the 
numbers of people with heart disease by 15%, and expen- 
ditures will have increased by $16 billion. The new CAD 
preventive drag is assumed to have been introduced in2010, 
adding $25.9 billion (1999 dollars) to costs without sub- 
stantially reducing the cost of treating CAD until 2025. 
By 2025, demographic changes will have further in- 
creased the numbers of people with heart disease by 46%, 
increasing heart disease cost by $47 billion over the 1999 
amount. Also, by 2025, benefits from the prevention of 
CAD will contribute to a reduction in the cost of treatment 
of $19 billion, partially offsetting the continuing preventive 
drug cost of $25.8 billion annually. As a result of the 
effectiveness ofCAD prevention, there will have been a 50% 
reduction in congestive heart failure and the need for heart 
transplants, which will reduce the cost of drugs for reversing 
heart failure to $5.1 billion (assuming 50% compliance), 
providing a savings of $6.7 billion in reduced hospitaliza- 
tions but leading to a $1.6 billion net increase in cost. The 
estimated need for heart ransplants is 29,000 in 2025 at an 
estimated annual cost of $4.4 billion, plus an annual medical 
management cost of $2.6 billion, totaling $7.0 billion. This 
equals the projected savings from reduced hospitalizations 
for congestive heart failure. 
Cost impact. In 2010, heart-disease costs will have in- 
creased because of demographic changes and the introduc- 
tion of a preventive treatments, totaling $143.9 billion or an 
increase of 41% over the $102 billion spent in 1999. By 
2025, there will be further increases in heart disease cost 
because of continuing demographic changes, combined with 
costs and projected savings from preventive treatment of 
coronary artery disease, new drugs to reverse heart failure, and 
advances inheart ransplants, totaling $157.5 billion in the cost 
of heart disease, or a 54% increase over the 1999 cost. 
Limitations 
The crystal ball that we have used to predict he future is 
built on a foundation of current physician, hospital, and 
nursing home practices, their costs, and the products emerg- 
ing from research that hold promise for prevention and 
better treatments. The opportunity for error in cost predic- 
tions is large, even though we think predicting future heart 
disease treatments hat will be used in practice over the next 
10-25 years is not unreasonable. The greater confidence in
the latter is based on the lag between when new knowledge 
becomes available and when it becomes useful and practical 
to provide it to patients across the U.S. 
Other potential biases that should be recognized include 
reductions in inpatient care and the growth of outpatient 
services that hold the promise of reducing cost. Also, as new 
techniques are developed, some will save costs, particularly if 
they are less invasive and require shorter ecovery periods. 
At the same time, individuals with congenital heart diseases 
are living longer, and their need for care can be expected to 
increase as the number of adults increases. There may be 
other treatment successes that will add to costs as we add 
years to people's lives. These possibilities are not explicitly 
taken into account in this report, nor are potential cost 
savings from changes in service delivery. 
DISCUSSION 
Our aging population is driving costs for heart disease care 
higher and higher. Expenditures for heart disease increase 
with age; average cost of heart diseases is more than four 
times higher for people over age 75 than for those under age 
65. Although cardiovascular disease accounts for almost 
17% of all health expenditures, this proportion doubles for 
people age 85 and older to 35% (3). We need to consider 
priorities for prevention versus treatment and rehabilitation 
and how to pay for preventive and curative care. In doing so, 
we need to examine cost and effectiveness carefully, taking 
into account that we may need to incur preventive care costs 
early to obtain benefits that may be delayed many years. 
This work represents an initial effort to examine specific 
scenarios and estimate their potential impact on future costs 
of heart disease in the U.S. (Fig. 3). 
Prevention isalmost always preferred over the suffering of 
heart disease and its treatment sequelae; however, current 
prevention technologies are not being used filly. Slightly 
more than half of all Americans with hypertension are 
receiving treatment, but only approximately half of these 
people have their blood pressure under control (1). Those at 
risk must be identified and must adopt the preventive 
treatments and health behaviors. Once these preventive 
strategies are adopted, these patients must adhere to the 
preventive regimen over time, possibly decades. Experience 
suggests that many will not adopt or adhere over time. 
Another consideration is cost. The number of people with 
the target risk factor---for example, hypercholesterolemia-- 
will far exceed the number of people who will develop the 
target condition. Cost-effectiveness analysis is one method 
for comparing the costs of preventive services over time with 
the benefits (added years of life), which may not occur until 
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Figure 3. Project costs of scenarios 1,2, 3, and combined scenarios 
m 2010 and 2025. 
years later. Scenario 2 predicts a new drug to prevent 
coronary heart disease, which would extend life at an 
average cost of $41,000 per Q ALY. 
Other opportunities for prevention may come from 
,creening for genetic risks at birth and providing people 
wlth individualized risk profiles by 2025. For some people, 
reduction of alcohol, changes in diet, and routine exercise 
may be more important to heart health than for others. Our 
current risk information provides average risks by age, 
gender, and comorbidity, not by individual, genetically 
specific risks, something we may be able to provide in the 
future. Individuals may still find it hard to adopt all 
heart-healthy behaviors, but they may be more highly 
motivated by knowledge of their own genetic susceptibilities 
and risks. 
Diagnosis and treatment of heart disease are likely to 
remain the major foci of cardiovascular medicine and will 
recur a majority of heart disease costs until 2025. Scenario 3
includes two possibilities, a new medication to reverse heart 
failure and the availability of swine hearts for heart trans- 
plantation. The predicted $3.5 billion net cost of reversing 
he~t failure is probably reasonable, whereas, the projection 
of no increase in cost for heart transplants may be overly 
optimistic. It is important o remember that, historically, 
advances in treatment generally have not been less expensive 
than current reatments. Even if our predictions are opti- 
mistic, one can be confident that there will be demand for 
advances in treatment that may add to years of life and 
maintain ahigh level of functioning throughout these years. 
Financing heart disease care into the next century will be 
an important and difficult challenge. As noted previously, 
current financing of health care is not meeting the needs of 
all Americans. Individuals who are poor, uninsured, and 
from minority populations are not enjoying the full benefits 
of the preventive and therapeutic services we have available 
today. Ensuring access to high-quality care would increase 
the current costs of the health care system, possibly by 10%. 
Even among people who are insured, it is estimated that not 
all of the needs of heart disease patients are being met. 
What it would cost to meet all of these needs is uncertain, 
but one might guess that it could add 10%-30% to costs. 
Adding this sum to our combined-scenario estimate of a 
54% cost increase by 2025, including demographic changes, 
plus advances in prevention and treatment, we might expect 
the total heart disease cost to rise as much as 64%-84% 
assuming we can find a way to pay for this additional cost. 
How do we finance these increases? The federal and state 
governments' shares of health care expenditures continue to 
increase. In 1997, total health care expenditures were $969 
billion, of which government paid 45%, private insurance 
paid 32%, and the remainder was mainly paid out of pocket 
(6). The government share will rise as the population ages 
and a higher proportion of citizens are over age 65 and 
receiving Medicare. Extrapolating from 1972 and 1997, 
when the government paid 41% and 45% of all costs, 
respectively, one could expect the government share to 
exceed 50% by 2010. Out-of-pocket costs are increasing as 
employers have shifted more of the costs of health benefits 
to the employees. By 2010, we can expect he percentage 
paid by private insurance to have declined, possibly to below 
30%, and the portion paid out of pocket o be rising. These 
trends can be expected to lead to tighter cost controls over 
the use of government dollars. Increases in out-of-pocket 
payments can be expected to reduce the number of people 
who can afford health insurance as well as the access to care 
for people with lower incomes, where expenditures on 
health care compete with housing, transportation, and food 
COSTS. 
What are reasonable options for the future financing of 
preventive and curative treatments for heart disease? One 
positive scenario would be sufficient growth in GDP that we 
could accommodate increases in heart disease costs without 
increasing the proportion of GDP dedicated to health care, 
now at 14%. The GDP would have to increase in real terms 
by 64o/0-84% by 2025, assuming that all other health care 
costs were increasing at the same rate as heart disease costs. 
Another possibility is that heart disease cost will be increas- 
ing at a faster ate than total health care cost in the future. 
This change may occur if people perceive the benefits of 
heart disease intervention and treatment to be greater than 
treatments for other diseases or if factors driving costs of 
other diseases are less intense than factors driving costs of 
heart disease. If  this change occurs, then the proportion of 
total health care cost expended on heart disease will rise 
above its current level of approximately 10%. 
Among the challenges of the new millennium will be to 
find creative and innovative ways to provide more efficient 
and more effective care to the growing number of people 
with heart disease. If  we can meet this challenge, then the 
full range of new and exciting prevention and treatment 
technologies should be available to all Americans. Ewe fail, 
then many Americans will never be able to afford and 
benefit from the scientific miracles to come. 
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